Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents

Clinical Chemistry

Volumn 51, Issue 12, 2005, Pages 2252-2256

  Singh, Uma ^a   Tabibian, James ^a   Venugopal, Senthil K ^a   Devaraj, Sridevi ^a   Jialal, Ishwarlal ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CATECHIN; CIGLITAZONE; CYTOKINE; EPIGALLOCATECHIN GALLATE; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; STATINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MODEL; MONOCYTE; SCREENING TEST; TH1 CELL; TIME;

ANTI-INFLAMMATORY AGENTS; CELL LINE, TUMOR; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; LIPOPOLYSACCHARIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28044446082     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.056093     Document Type: Article

References (34)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis [Review]. Circulation 2002;105:1135-43.
3. Devaraj S, Harris A, Jialal I. Modulation of monocyte-macrophage function with α-tocopherol: implications for atherosclerosis [Review]. Nutr Rev 2002;60:8-14.
4. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101:2149-53.
5. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
6. Wirtz PH, von Kanel R, Rohleder N, Fischer JE. Monocyte proinflammatory cytokine release is higher and glucocorticoid sensitivity is lower in middle aged men than in women independent of cardiovascular risk factors. Heart 2004;90:853-8.
7. Jialal I, Devaraj S. Oxidative stress, inflammation, and diabetic vasculopathies: the role of a tocopherol therapy [Review]. Free Radie Res 2002;36:1331-6.
8. van Tits LJ, Demacker PN, de Graff J, Hak-Lemmers HL, Stalenhoef AF. α-Tocopherol supplementation decreases production of superoxide and cytokines by leukocytes ex vivo in both normolipidemic and hypertriglyceridemic individuals. Am J Clin Nutr 2000;71:458-64.
9. Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease [Review]. Curr Drug Targets Inflamm Allergy 2003;2:257-65.
10. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004;177:161-6.
11. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.
12. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
13. Staels B. PPARγ and atherosclerosis. Curr Med Res Opin 2005; 21:513-20.
14. Castrillo A, Tontonoz P. PPARs in atherosclerosis: the clot thickens [Review]. J Clin Invest 2004;114:1538-40.
15. Khan BV, Navalkar S, Khan QA, Rahman ST, Parthasarathy S. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J Am Coll Cardiol 2001;38:1662-7.
16. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001;37:440-4.
17. Devaraj S, Li D, Jialal I. The effects of α-tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1β secretion, and monocyte adhesion to endothelium. J Clin Invest 1996;98:756-63.
18. Banka CL, Black AS, Dyer CA, Curtiss LK. THP-1 cells form foam cells in response to coculture with lipoproteins but not platelets. J Lipid Res 1991;32:35-43.
19. Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-κB. Cell Immunol 2002;220:83-95.
20. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 2001;69:959-62.
21. Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of α-tocopherol supplementation. Circulation 2000;102:191-6.
22. Venugopal SK, Devaraj S, Yang T, Jialal I. α-Tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-α. Diabetes 2002;51:3049-54.
23. Devaraj S, Venugopal SK, Singh U, Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{α} and -{β}. Diabetes 2005;54:85-91.
24. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104:3103-8.
25. Hofmann CS, Sonenshein GE. Green tea polyphenol epigallocatechin-3 gallate induces apoptosis of proliferating vascular smooth muscle cells via activation of p53. FASEB J 2003;17:702-4.
26. Rosenkranz S, Knirel D, Dietrich H, Flesch M, Erdmann E, Bohm M. Inhibition of the PDGF receptor by red wine flavonoids provides a molecular explanation for the "French paradox". FASEB J 2002;16:1958-60.
27. Singh U, Jialal I. Anti-inflammatory effects of α-tocopherol. Ann N Y Acad Sci 2004;1031:195-203.
28. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.
29. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35.
30. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF-, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 1996;271:665-8.
31. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-10.
32. Sattler KJ, Woodrum JE, Galili O, Olson M, Samee S, Meyer FB, et al. Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor κB activation and C-reactive protein expression in human carotid artery plaques. Stroke 2005;36:14-20.
33. Devaraj S, Jialal I. α-Tocopherol supplementation decreases serum CRP and monocyte IL-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med 2000;29:790-2.
34. Jialal I, Devaraj S, Kaul N. The effect of α-tocopherol on monocyte proatherogenic activity [Review]. J Nutr 2001;131:389S-94S.